KRAS and pancreatic neoplasm: Although a variety of genetic aberrant markers have been identified in human pancreatic cancer lesions, the most frequent mutations were identified in K-ras, and the closely following events were the inactivation of the tumor suppressors of p16, ARF, p53 and SMAD4 [12]–[14].